Fulgent Genetics Inc (FLGT) - Net Assets
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has net assets worth $995.99 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.09 Billion) and total liabilities ($93.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FLGT strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $995.99 Million |
| % of Total Assets | 91.44% |
| Annual Growth Rate | 80.36% |
| 5-Year Change | -5.07% |
| 10-Year Change | 1931.45% |
| Growth Volatility | 300.13 |
Fulgent Genetics Inc - Net Assets Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Fulgent Genetics Inc.
Annual Net Assets for Fulgent Genetics Inc (2014–2025)
The table below shows the annual net assets of Fulgent Genetics Inc from 2014 to 2025. Also explore Fulgent Genetics Inc annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.11 Billion | -1.99% |
| 2024-12-31 | $1.13 Billion | -0.36% |
| 2023-12-31 | $1.13 Billion | -10.76% |
| 2022-12-31 | $1.27 Billion | +8.92% |
| 2021-12-31 | $1.17 Billion | +104.76% |
| 2020-12-31 | $569.39 Million | +587.86% |
| 2019-12-31 | $82.78 Million | +58.36% |
| 2018-12-31 | $52.27 Million | -3.25% |
| 2017-12-31 | $54.03 Million | -0.83% |
| 2016-12-31 | $54.48 Million | +958.67% |
| 2015-12-31 | $5.15 Million | +205.58% |
| 2014-12-31 | $1.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fulgent Genetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 54027000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $529.95 Million | 47.66% |
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $7.51 Million | 0.68% |
| Other Components | $574.52 Million | 51.67% |
| Total Equity | $1.11 Billion | 100.00% |
Fulgent Genetics Inc Competitors by Market Cap
The table below lists competitors of Fulgent Genetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COOR Service Management AB
ST:COOR
|
$514.85 Million |
|
Triductor Technology (Suzhou) Inc.
SHG:688259
|
$514.87 Million |
|
CCCG Real Estate Corp Ltd
SHE:000736
|
$514.92 Million |
|
Shanxi Huhua Group Co Ltd
SHE:003002
|
$515.09 Million |
|
Pilani Investment and Industries Corporation Limited
NSE:PILANIINVS
|
$514.74 Million |
|
Inner Mongolia Xinhua Distribution Group Co.Ltd.
SHG:603230
|
$514.73 Million |
|
Shenzhen Fluence Technology PLC
SHE:300647
|
$514.62 Million |
|
Zhejiang Jindun Fans Co Ltd
SHE:300411
|
$514.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fulgent Genetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,133,228,000 to 1,111,989,000, a change of -21,239,000 (-1.9%).
- Net loss of 60,513,000 reduced equity.
- Share repurchases of 13,920,000 reduced equity.
- Other comprehensive income increased equity by 7,880,000.
- Other factors increased equity by 45,314,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.51 Million | -5.44% |
| Share Repurchases | $13.92 Million | -1.25% |
| Other Comprehensive Income | $7.88 Million | +0.71% |
| Other Changes | $45.31 Million | +4.08% |
| Total Change | $- | -1.87% |
Book Value vs Market Value Analysis
This analysis compares Fulgent Genetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 207.09x to 0.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.10 | $19.73 | x |
| 2015-12-31 | $0.40 | $19.73 | x |
| 2016-12-31 | $3.08 | $19.73 | x |
| 2017-12-31 | $3.05 | $19.73 | x |
| 2018-12-31 | $2.91 | $19.73 | x |
| 2019-12-31 | $4.42 | $19.73 | x |
| 2020-12-31 | $23.67 | $19.73 | x |
| 2021-12-31 | $37.41 | $19.73 | x |
| 2022-12-31 | $40.91 | $19.73 | x |
| 2023-12-31 | $38.14 | $19.73 | x |
| 2024-12-31 | $37.48 | $19.73 | x |
| 2025-12-31 | $36.13 | $19.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fulgent Genetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.75%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.09x
- Recent ROE (-5.44%) is above the historical average (-33.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -254.33% | -335.13% | 0.60x | 1.26x | $-4.45 Million |
| 2015 | -161.56% | -86.82% | 1.64x | 1.13x | $-8.83 Million |
| 2016 | -9.89% | -29.48% | 0.31x | 1.07x | $-10.84 Million |
| 2017 | -4.93% | -14.21% | 0.33x | 1.05x | $-8.06 Million |
| 2018 | -8.59% | -21.02% | 0.39x | 1.05x | $-9.72 Million |
| 2019 | 0.44% | 1.13% | 0.37x | 1.07x | $-7.91 Million |
| 2020 | 37.64% | 50.82% | 0.60x | 1.23x | $157.37 Million |
| 2021 | 9.00% | 10.51% | 0.78x | 1.10x | $-11.54 Million |
| 2022 | 11.32% | 23.17% | 0.45x | 1.09x | $16.73 Million |
| 2023 | -14.77% | -58.03% | 0.23x | 1.09x | $-281.44 Million |
| 2024 | -3.77% | -15.07% | 0.23x | 1.08x | $-156.03 Million |
| 2025 | -5.44% | -18.75% | 0.27x | 1.09x | $-171.71 Million |
Industry Comparison
This section compares Fulgent Genetics Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $610,496,125
- Average return on equity (ROE) among peers: -51.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fulgent Genetics Inc (FLGT) | $995.99 Million | -254.33% | 0.09x | $514.81 Million |
| Agilent Technologies Inc (A) | $5.29 Billion | 10.38% | 1.04x | $42.70 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.31 Million | -9.31% | 2.52x | $10.52 Million |
| Applied DNA Sciences Inc (APDN) | $-1.47 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $-2.46 Million | 0.00% | 0.00x | $247.95 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $17.63 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $167.75 Million | -24.78% | 0.80x | $4.24 Billion |
| Burning Rock Biotech Ltd (BNR) | $768.41 Million | -85.07% | 0.35x | $105.68 Million |
| CareDx Inc (CDNA) | $-150.67 Million | 0.00% | 0.00x | $2.42 Billion |
| Check Cap Ltd (CHEK) | $41.31 Million | -46.25% | 0.10x | $9.42 Million |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more